| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 35.2 | 38.2 |
| Gross profit | 26.3 | 26.3 |
| Net income | -5.0 | -17.5 |
| EPS (diluted, $ a share) | $-0.03 | $-0.10 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.8% |
|---|---|
| Gross margin | 74.6% |
| Operating margin | -4.7% |
10-Q filed with the SEC, NASDAQ: HRTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Heron Therapeutics, Inc.: key numbers
- Share price
- $0.2843Close, Nov 16
- Market cap
- $54.1M
- Shares outstanding
- 190.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Heron Therapeutics, Inc.
All →Heron Therapeutics Financial Results
Heron Therapeutics reported Q3 2026 net revenue of $35.3 million, a 7.8% decrease year-over-year, driven by a decline in its Oncology franchise despite growth in Acute Care products ZYNRELEF and APONVIE. The company also announced a definitive agreement to sell substantially all of its assets to CorMedix Therapeutics, subject to stockholder approval. Heron ended the quarter with $23.4 million in cash and cash equivalents and did not provide forward financial guidance.
- Counterparty
- CorMedix Therapeutics
Heron Therapeutics Divestiture to CorMedix Inc. for $145M
Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.
- Value
- $145M
- Counterparty
- CorMedix Inc.
Heron Therapeutics Licensing Deal with Long Grove Pharmaceuticals, LLC
Heron Therapeutics entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals and Capstone Development Services. The agreement grants Heron an exclusive license to import, distribute, and market certain products in the U.S. in exchange for regulatory milestones, sales-based milestones, and royalty payments.
- Counterparty
- Long Grove Pharmaceuticals, LLC
- Term
- 10 years